2016-372 – Mayo Clinic Researchers have discovered that microbiome associated protein 1 (MAP1)B1 is the antigen for PCA-2 autoantibodeis.
2015-311 – Mayo Clinic has discovered that HEATR1 is a novel Akt regulator and a predictor for chemoradioresistance.
2015-312 – Mayo Clinic has discovered that the Parkin protein is a mitotic regulator. Cancer cells with deficiency or mutations in Parkin have an increase in mitotic regulator expression leading to tumorigenesis and an increase in sensitivity of Pk1 and Aurora kinase inhibitors. This newly identified mechanism has revealed that Parkin mutations may be used as a biomarker for measuring the sensitivity of... Read More
2015-164 – Mayo Clinic has discovered that WSB1 can be used as a diagnostic marker for tumor metastasis and a therapeutic target.
Methods of Treating Cancer by Using PD1 and PD-L1 inhibitors by Using Soluble PD-L1 Levels as a Biomarker
2008-042 – Mayo Clinic has patent rights claiming methods of using PD1 or PD-L1 antibodies to treat cancer by using soluble PD-L1 levels in the serum as a biomarker.
2004-239 – Mayo Clinic has patent rights claiming the use of PD1 and PD-L1 antibodies to treat cancer. The patent rights also include diagnostic and prognostic claims.
2016-135 – The advent of next-generation sequencing has opened the door to widespread identification of somatic mutations in tumor genomes. These somatic mutations can be utilized to identify “true clonal mutations”, or those that are responsible for driving tumor growth in an individual, and therefore could be useful in the identification of therapeutic targets. The primary issue in the identification... Read More
2013-206 – This invention has benefit over other methods since it directly quantitates the mAb without the need for interaction with the antigen. By monitoring tryptic peptides from the unique variable regions of the therapeutic mAb and comparing them to the constant regions of a non-human antibody added as an internal standard, the mAb can be measured. This method is superior to other methods using... Read More
2012-139 – In normal healty individuals, the plasma cells produce numerous immunoglobulins each with its own unique protein sequence and hence a unique mass. When examined together, the distribution of the masses forms a Gaussian distribution. Patients whom have plasma cells that overproduce immunoglobulins (M-proteins) are at risk for developing serious diseases such as multiple myeloma. Currently,... Read More
2013-180 – Snail is a protein that, when it is active induces an invasive phenotype in cancer cells. Inactivation of Snail can occur by phosphorylation of its amino acid residue serine 11 (see attached publication). We have generated a phosphosite specific antibody that targets the protein Snail, when it is phosphorylated at serine 11. This antibody can be utilized as a research tool, but also allows to... Read More
2012-110 – Currently, cancerous pigmented lesions, i.e. malignant melanoma, are diagnosed based on morphological features such as cell size and the overall architecture of the lesion under a microscope. Risk of metastasis is primarily assessed by the depth of invasion of morphologically atypical cells into the skin (so-called Breslow depth), which can be misleading and often triggers unnecessary... Read More
A Novel Method to Identify Antigens Which Act Co-Operatively To Treat Established Tumors Using Viral-Expressed cDNA Libraries
2012-049 – We describe a novel technology to define new repertoires of tumor antigen(s) which work alone or in combination to generate anti tumor immune responses. Definition of arrays of antigens which co-operate in vivo to cure established tumors will inform future strategies for novel clinical vaccines through the use of vesicular stomatis virus with cDNA libraries constructed with selected, relevant... Read More
2011-271 – We identified a novel translocation of TP63 gene which encodes p63 protein. The translocation leads to overexpression of a dominant negative TP63 isoform. Dominant negative TP63 isoforms lead to inactivation of p53, the most important tumor suppressor known. The translocation can be useful for diagnosis and subclassification of certain peripheral T cell lymphomas, B-cell lymphomas... Read More
2011-245 – Immune responses directed toward many cancers are characterized by targeted cell-killing activities mediated by cytotoxic T cells (a.k.a. Thl responses). However, certain tumors such as bladder cancer, instead appear to elicit immune responses that are traditionally linked with allergies (a.k.a. Th2 responses). These immune responses also include the tissue recruitment of rare white blood... Read More
2011-184 – Methods and Materials for Assessing Responsiveness PARP Inhibitors and Platinating Agents Methods and materials have been developed for assessing responsiveness to PARP inhibitors and platinating agents by using levels of non-homogous end-joining (NHEI) pathway members to determine if cancer cells that are homologous recombination (hr) - deficient are likely to be susceptible or resistant... Read More
2010-299 – Molecular breast imaging (MBI) is a molecular imaging technique that can be used for the detection of breast cancer. MBI can detect breast tumors not visible on mammography or ultrasound. MBI images usually take 5-10 minutes to acquire 1 view. A slant-hole collimator can be used to estimate tumor depth and enable tumor biopsy using a radiolabeled guide. However, the long imaging time of 5-10... Read More
2010-155 – Suppressive Monocytes as Markers of Immune & Therapeutic Responses Mayo Clinic researchers have identified immune phenotypes that can be used to measure the level of systemic immune suppression in patients with cancer and sepsis. Subsets of peripheral blood leukocytes can be measured using standard flow cytometry methods and used as prognostic markers in cancer and sepsis patients. ... Read More
2009-379 – Technology Description Patients with extensive, longstanding inflammatory bowel diseases (ulcerative colitis or Crohn’s disease), which are diseases of chronic colonic inflammation, are at risk for colorectal cancer (CRC). Surveillance of this at-risk population remains challenging. Mayo Clinic researchers have identified biomarkers for colorectal cancer in inflammatory bowel disease... Read More
2009-374 – Technology Description An immunotherapy approach that delivers multiple antigens within a vesicular stomatitis virus (VSV) vector. The delivery of multiple antigens allows for a multipronged immune response against a tumor while the VSV vector serves as an activator of the innate and adaptive immune response. A three antigen combination delivered via a VSV vector has been demonstrated to be... Read More
2009-366 – A method and system for producing 3-dimensional ultrasound images of a patient’s breast and also producing planar emission images from a radiopharmaceutical is described. The system allows perfect co-registration of both the ultrasound image and the emission image, thereby allowing comparison of anatomical and functional features of the breast tissue. The system comprises 3 primary components... Read More
2009-264 – Conventionally, nuclear medicine gamma cameras employ an energy window centered in the primary gamma ray energy emitted by the radioisotope being detected. For example, with Tc-99m, a 20% energy window (from 126-154 keV) is centered on the 140 keV gamma rays. At lower energies, scatter within the patient and the gamma camera degrade image quality and these events are not considered useful. ... Read More
2009-211 – Technology Description Mayo Clinic researchers have discovered that USP10 is the missing link between autophagy and cancer formation. USP10 is a regulator of p53 degradation and activity. USP10 is stabilized upon DNA damage and deubiquitinates p53, reversing Mdm-2 induced nuclear export and degradation. USP10 suppresses tumor cell proliferation in cells expressing wild-type p53. USP10... Read More
2009-196 – Technology Description There is no available test that predicts the onset of preeclampsia, and current diagnostic methodologies of blood pressure and proteinuria measurement need improvement. Mayo Clinic researchers have discovered an epithelial cell type (podocyte) present in the urine of patients with preeclampsia, and these cells are present in the urine of patients several weeks before... Read More
2006-290 – Technology Description Expression of B7-H3 on the cell surface of tumor cells and tumor-associated vasculature is greatly increased in prostate and renal cancers. B7-H3 is predictive of disease progression and poor survival and is a therapeutic target for tumor cells and tumor-associated vessels by antibody directed cytotoxicity. Application B7-H3 may be a useful prognostic marker for... Read More
2006-104 – Soluble and Extracellular Markers for Early Detection of Prostate Cancer A discriminating panel of genes has been identified that may be used for early detection of prostate cancer. Many of these genes demonstrate prostate-specific expression. Genes encoding extracellular and membrane proteins were selected to facilitate a minimally invasive (e.g. blood sample) form of detection. ... Read More
Fluorescent In Situ Hybridization (FISH) Probe Development to Detect Immunoglobulin Light Chains Kapa (IGK) and Lambda (IGL) Translocations
2005-072 – Lymphoma, the cancer to the lymph glands and lymphocytes develop as a consequence of acquired genetic/chromosomal changes. In clinical practice identification of these genetic changes are critical in diagnosis and treatment of lymphoma patient. We have developed fluorescent in situ hybridization (FISH) for two targets frequently involved in lymphoma development. We believe that these probes... Read More
Tandem Mass Spectrometry (MS/MS) of Thiopurine Methyltransferase (TPMT) Reaction Products in order to Quantitate TPMT Enzyme Activity
2005-017 – This invention provides methods and materials related to the measurement of TPMT enzymatic activity in biological samples. The assay involves the incubation of a cell lysate with a TPMT substrate and S-adenosyl-L-methionine (SAM), which acts as a methyl donor, and an isotopically labeled internal standard corresponding to the enzymatically produced methylation product of the TPMT substrate.... Read More
2002-227 – The enzyme utilizes S-adenosylmethionine to methylate aresenite to monomethylarsonate, and can further methylate this product to form dimethylarsinic acid. Known substrates are Aresenite, Methylarsonous acid, Methylarsonous acid. It is known to be expressed in liver, kidney and brain. Arsenic exposure outcomes (death, cancer, neurotoxicity, liver damage, and cardiovascular disease et. al.)... Read More